Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company pioneering novel therapies for hematologic disorders through innovative research in iron metabolism and red blood cell biology. This page serves as the definitive source for verified corporate developments, research milestones, and regulatory updates.
Investors and researchers will find timely updates on clinical trials for lead candidates including bitopertin (targeting erythropoietic protoporphyria) and DISC-0974 (for anemia management). Our curated news collection covers essential updates, partnership announcements, and scientific presentations without speculative commentary.
Key content categories include phase trial results, FDA communications, intellectual property developments, and peer-reviewed research findings. All materials are vetted for accuracy and relevance to therapeutic advancements in hematology.
Bookmark this page for streamlined access to IRON's latest progress in developing first-in-class therapies that address unmet needs in iron-related disorders. Check regularly for objective updates on pipeline candidates and corporate strategy.
Disc Medicine (NASDAQ:IRON) has appointed Steve Caffé, MD as Chief Regulatory Officer. Dr. Caffé brings over 25 years of experience in global product development and regulatory affairs, with expertise in hematology, oncology, and rare diseases. He previously served as Head of Regulatory Affairs at CRISPR Therapeutics, contributing to the approval of Casgevy® for sickle cell disease and beta thalassemia.
Dr. Caffé's appointment comes at a important time for Disc Medicine as it transitions to a late-stage hematology company. His extensive experience, including contributions to over 40 new drug approvals worldwide, is expected to be valuable as Disc prepares for significant trial initiations across its portfolio in the coming year.
As part of his appointment, Dr. Caffé received an inducement equity award, including stock options and restricted stock units, subject to vesting conditions.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company focusing on hematologic diseases, has announced its participation in four upcoming investor conferences in September 2024. The company's management will engage in fireside chats at the following events:
- 2024 Wells Fargo Securities Healthcare Conference (Sept. 6, 10:15 a.m. ET)
- Morgan Stanley 22nd Annual Global Healthcare Conference (Sept. 6, 1:05 p.m. ET)
- H.C. Wainwright 26th Annual Global Investment Conference (Sept. 11, 9:30 a.m. ET)
- 2024 Cantor Global Healthcare Conference (Sept. 19, 8:00 a.m. ET)
Live webcasts of these fireside chats will be accessible through Disc Medicine's investor relations website, with archived replays available after each event.
Disc Medicine (NASDAQ:IRON) reported Q2 2024 financial results and provided a business update. The company presented positive data for all three programs at the EHA 2024 Congress, demonstrating potential efficacy for bitopertin in EPP and DISC-0974 in anemia of myelofibrosis. Disc plans to provide updates on regulatory interactions for these programs in H2 2024. The company strengthened its financial position through a $178 million common stock offering, ending Q2 with $501 million in cash, expected to fund operations into 2027.
Financial highlights include R&D expenses of $23.5 million, up from $12.1 million in Q2 2023, and G&A expenses of $7.4 million, up from $5.2 million. The net loss for Q2 2024 was $26.4 million, compared to $15.9 million in Q2 2023. Disc Medicine continues to advance its portfolio, with upcoming milestones including regulatory discussions and data readouts in H2 2024.
Disc Medicine, a clinical-stage biopharmaceutical company (NASDAQ: IRON), announced an underwritten offering of 4,944,000 shares at $36 per share, expecting to raise approximately $178 million. The offering, closing on June 17, 2024, is led by Frazier Life Sciences and Logos Capital, with participation from significant institutional investors. Proceeds will fund ongoing and new clinical research, working capital, and other corporate purposes. Leerink Partners is the sole bookrunner.
Disc Medicine presented positive clinical data at the European Hematology Association (EHA) 2024 Congress. Key highlights include:
1. Bitopertin in erythropoietic protoporphyria (EPP): AURORA study results showed significant reductions in protoporphyrin IX (PPIX) and improvements in light tolerance and quality of life.
2. DISC-0974 in myelofibrosis (MF): Phase 1b trial data demonstrated durable increases in hemoglobin levels and reductions in transfusion burden.
3. DISC-3405 in healthy volunteers: Phase 1 trial showed sustained hepcidin induction and serum iron suppression.
Disc Medicine highlighted these advancements supporting their ongoing development and potential therapeutic applications.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical firm, will present at the Jefferies Global Healthcare Conference on June 6th at 1:00 pm ET. The company focuses on developing treatments for serious hematologic diseases. A live webcast and an archived replay of the presentation will be accessible on the company's investor relations webpage.
Disc Medicine, a clinical-stage biopharmaceutical company, will present data from its hematology portfolio at the European Hematology Association (EHA) 2024 Congress in Madrid from June 13-16, 2024.
Key presentations include:
- AURORA trial: Phase 2, double-blind study of Bitopertin in erythropoietic protoporphyria.
- BEACON trial: Phase 2, open-label study of Bitopertin in erythropoietic protoporphyria.
- Phase 1b study: DISC-0974 in myelofibrosis patients with anemia, featuring a larger dataset and longer follow-up.
- Phase 1 study: Initial safety and pharmacodynamic data on DISC-3405 in healthy volunteers.
Management will discuss the data on June 14th at 8:00 am ET. Full abstracts are available on the EHA conference website.
Disc Medicine, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright BioConnect Investor Conference on May 20th. The company focuses on developing treatments for hematologic diseases. The event will feature a fireside chat available via live webcast and archived replay on the company's website.
Disc Medicine, Inc. (NASDAQ:IRON) reported its financial results for Q1 2024, ending with $343M in cash. The AURORA trial showed positive results for bitopertin in EPP patients, reducing toxic PPIX levels and improving quality of life. The company plans to present more data from BEACON and AURORA in Q2 2024, with positive regulatory interactions expected in the second half of the year. DISC-0974 and DISC-3405 also show promising results with upcoming data releases.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
